Brief update clascoterone phase 3 - Breezula Research/Science 3/20/2024
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
View this post in the Community →
Similar Community Posts Join
5 / 111 resultscommunity Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community Is there any new drug that looks promising ?
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Breezula will hit the market in 2026, Cosmo Pharmaceuticals statement!
Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.
Related Research
6 / 64 results
research Biotechs Target Stagnant Baldness Market
New drug shows promise for better hair growth in baldness treatment.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Experimental and Early Investigational Drugs for Androgenetic Alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Androgenetic Alopecia: Combing the Hair Follicle Signaling Pathways for New Therapeutic Targets and More Effective Treatment Options
New treatments for hair loss may target specific pathways and generate new hair follicles.
research Antiandrogens and Androgen Inhibitors in Dermatologic Treatments
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Androgenetic Alopecia: An Update Of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.